Logo image
Back
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients
Journal article   Open access   Peer reviewed

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients

Valerianna K. Amorosa, Jihad Slim, Karam Mounzer, Christopher Bruno, Margaret Hoffman-Terry, Zachariah Dorey-Stein, Thomas Ferrara, Jay R. Kostman and Vincent Lo Re
Antiviral therapy, v 15(1), pp 91-99
01 Jan 2010
DOI: https://doi.org/10.3851/IMP1492
PMID: 20167995
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://europepmc.org/articles/pmc2854539View
Accepted (AM)Open Access (License Unspecified),  Open
url
https://doi.org/10.3851/IMP1492View
Published, Version of Record (VoR) Open

Abstract

Infectious Diseases Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology Virology
Background: It remains unclear if certain antiretroviral medications, particularly abacavir, compromise response to HCV therapy. Such data could inform the selection of appropriate antiretrovirals in HIV/HCV-coinfected patients. The aim of this study was to determine if use of abacavir, as well as other antiretrovirals, was associated with reduced response to pegylated interferon (PEG-IFN) plus ribavirin. Methods: A cohort study was performed among antiretroviral-treated HIV/HCV-coinfected patients initiating PEG-IFN plus ribavirin between January 2001 and June 2007 at six sites in the United States. Abacavir and other antiretrovirals represented exposures of interest. Study outcomes included an early virological response (>= 2 log IU/ml decrease in HCV viral load at 12 weeks) and sustained virological response (undetectable HCV viral load 24 weeks after treatment discontinuation). Results: Among 212 patients, 74 (35%) received abacavir. For patients infected with HCV genotype 1 or 4, no differences were observed between abacavir users and non-users in early virological response (26 [40%] versus 53 [44%]; adjusted odds ratio [OR] 1.00; 95% confidence interval [CI] 0.50-2.00) or sustained virological response (8 [13%] versus 13 [12%]; adjusted OR 1.34; 95% CI 0.50-3.62). Among genotype 2 and 3 patients, rates of early virological response (7 [78%] versus 16 [89%]; OR 0.44; 95% CI 0.05-3.76) and sustained virological response (3 [33%] versus 8 [44%]; OR 0.63; 95% CI 0.12-3.32) were also similar between abacavir users and non-users. No association was found between other antiretrovirals and a lack of early or sustained response. Conclusions: Use of abacavir or other antiretroviral medications was not associated with reduced early or sustained virological response rates.

Metrics

11 Record Views
19 citations in Web of Science
28 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Infectious Diseases
Pharmacology & Pharmacy
Virology
Logo image